Safety and Tolerability of PRO-087 Versus Xyel Ofteno® and Systane Ultra®, on the Ocular Surface of Healthy Subjects

Phase I Clinical Study, to Evaluate the Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-087 Versus Xyel Ofteno® and Systane Ultra®, on the Ocular Surface of Ophthalmologically and Clinically Healthy Subjects

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03524157

Acronym

PRO-087/I

Enrollment

Registered

2018-05-14

Start date

2017-07-17

Completion date

2018-03-27

Last updated

2019-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye Syndromes, Lubricant Allergy, Tear Disorder

Keywords

Humylub PF, artificial tears, Ophthalmic lubricant, Chondroitin sulfate, Sodium hyaluronate

Brief summary

Detailed description

Phase I clinical study, to evaluate the safety and tolerability of the preservative-free ophthalmic solution PRO-087 versus Xyel Ofteno® and Systane Ultra®, on the ocular surface of ophthalmological and clinically healthy subjects. Objective: To evaluate the safety and tolerability of the preservative-free formulation PRO-087 manufactured by Laboratorios Sophia S.A. of C.V. on the ocular surface of clinically healthy subjects. Hypothesis: The ophthalmic solution PRO-087 presents a profile of safety and tolerability similar to comparators in healthy subjects Methodology: Phase I clinical trial, controlled, of parallel groups, double blind, randomized, exploratory. Study period: 3 to 4 months treatment duration: 10 days Number of patients: 30 subjects, divided into 3 groups,10 subjects (20 eyes) exposed by group. Diagnosis and main inclusion criteria: * Systemically and ophthalmologically healthy subjects * Signed informed consent. * Age between 18 to 40 years * Both genders * Blood tests complete, blood count (BHC), three element blood chemistry (QS) and liver function tests, within normal parameters * Visual capacity 20/30 or better Test product, dose and route of administration: \- PRO-087. Chondroitin sulfate 0.18% / 0.1% sodium hyaluronate, ophthalmic solution preservative free. made by Laboratorios Sophia, S.A. of C.V., Zapopan, Jalisco, Mexico. Dosage: 1 drop 4 times a day during the waking period, both eyes Route of administration: topical ophthalmic. Reference product, dose and route of administration: 1. Xyel Ofteno®. Xanthan gum 0.09% / Chondroitin sulfate 0.1% / preservative-free ophthalmic solution. made by Laboratorios Sophia, S.A. of C.V., Zapopan, Jalisco, Mexico. Dosage: 1 drop 4 times a day during the waking period, both eyes Route of administration: topical ophthalmic. 2. Systane Ultra®. Polyethylene glycol 400 0.4%, propylene glycol 0.3%. made by Alcon Laboratories, Inc. Dosage: 1 drop 4 times a day during the waking period, both eyes Route of administration: topical ophthalmic. Evaluation criteria: Primary security outcome variables: * Goblet cells density . * Presence of adverse events. * Intraocular pressure. * Visual ability * Laboratory tests * Epithelial defects in cornea and conjunctiva. * Ophthalmological signs: conjunctival hyperemia, chemosis. Secondary outcome variables: * Tear film rupture time * Life signs: heart rate, respiratory frequency systemic blood pressure. * Subsequent segment Primary outcome variables of tolerability: * Burning * Foreign body sensation * Itching * Eye comfort index Statistical methodology: The data will be expressed with measures of central tendency: mean and standard deviation for the quantitative variables. The qualitative variables will be presented in frequencies and percentages. The statistical analysis will be carried out through the Kruskal-Wallis test for quantitative variables. The difference between the qualitative variables will be analyzed by means of chi square (Chi2). An alpha ≤ 0.05 will be considered significant.

Interventions

DRUGPRO-087

The intervention period consists of a therapy with PRO-087administered 4 times a day in the waking period for 10 days. with a security call to day 13.

DRUGSystane Ultra

The intervention period with active comparator drug consists of a therapy with systane administered 4 times a day in the waking period for 10 days. with a security call to day 13.

DRUGXyel Ofteno

The intervention period with active comparator drug consists of a therapy with Xyel administered 4 times a day in the waking period for 10 days. with a security call to day 13.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

Blinding It will consist in the elimination of the primary label (commercial) in the case of Xyel Ofteno® and Systane Ultra® and the placement of a label identical to the other interventions. Because the bottle in which Systane Ultra® is packaged differs in the color and shape of the lid used by Xyel Ofteno® and PRO-087, a masking will be carried out on the primary packaging which will be identical for the three interventions.The allocation sequence will be generated by personnel assigned. The research center will receive a set of envelopes which will contain the intervention number individually. The envelopes will be identical on the outside. Each of these envelopes will be shown to the participants for their election by the principal investigator or by a designated member of their team. The blinding will correspond to the research subject and the principal investigator. In addition, the statistical analysis will be carried out in a blinded manner for the all analysis.

Intervention model description

Phase I clinical trial, controlled, of parallel groups, double blind, randomized, exploratory.

Eligibility

Sex/Gender

ALL

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* Systemically and ophthalmologically healthy subjects * Signed informed consent. * Age between 18 to 40 years. * Both genders * Blood tests \[complete blood count (BHC), three element blood chemistry (QS) and liver function tests (PFH)\] within normal parameters * Visual capacity 20/30 or better

Exclusion criteria

* Subjects with a history of hypersensitivity to any of the components of the research products. * Subject users of topical ophthalmic medications of any pharmacological group. * Subject users of medication by any other route of administration. * Women who are pregnant or breastfeeding. * Women without a history of hysterectomy, oophorectomy or hysterectomy, who do not ensure a hormonal contraceptive method or intrauterine device during the study period. * Subjects with participation in clinical research studies 90 days prior to inclusion in the present study. * Diagnosis of liver disease or triple the normal upper value of any of the following liver enzymes: aspartate transferase (AST), alanine transferase (ALT) or bilirubin. * Inability to attend or answer the evaluations made in each of the visits. * Positive smoking (specified as cigarette consumption regardless of quantity and frequency) * Positive alcoholism (specified as the consumption of alcoholic beverages, regardless of quantity and frequency, during the study intervention period). * Users of contact lenses.

Design outcomes

Primary

Measure	Time frame	Description
Goblet Cell Density (GCD)	will be evaluated at the end of the treatment at the final visit (day 10)	the cells will be measured per square millimeter, it is a continuous variable taken by means of cytology per impression, the normal value is higher than 500 cells per square millimeter

Secondary

Measure	Time frame	Description
Intraocular Pressure (IOP)	will be evaluated at the end of the treatment at the final visit (day 10)	the intraocular pressure will be evaluated by means of the Goldman applanation tonometry whose unit of measurement is millimeters of mercury (mmHg), it is a continuous variable and its normality range is between 11 - 21 mmHg
Epithelial Defects (ED)	will be evaluated at the end of the treatment at the final visit (day 10)	The epithelial defects will be evaluated by means of two stains, green lysine and fluorescein, it is a discrete variable that will be realized by direct observation, it will be staged according to the degrees of the oxford scale that go from 0 to 5 (0-V) according to its severity, where 0 is the normal lower limit and 5 the upper limit of defects.
Breakup Time (BUT)	will be evaluated at the end of the treatment at the final visit (day 10)	breakup time lacrimal film is a continuous variable that will be measured in seconds, evaluating the time it takes to break it, is done by direct counting and the normality range and mayor to 10 seconds.
Conjunctival Hyperemia (CH)	will be evaluated at the end of the treatment at the final visit (day 10)	Conjunctival hyperemia will be evaluated as an ordinal variable, by direct observation and staged using the Efron scale as Normal / Very mild / Mild / Moderate / Severe. Based on this scale, the normal and mild stages are considered without pathologies or normal. Moderate and severe are considered pathological.
Presence of Adverse Events (AEs)	during the 13 days of evaluation, including the safety call (day 13).	the adverse events will be evaluated with a scale of Present / Absent, it is a nominal variable, the normal value is absent.
Ocular Burning (OB)	will be evaluated at the end of the treatment at the final visit (day 10)	ocular burning is a nominal variable that will be evaluated by direct questioning to the research subject, then it will be staged according to the following scale: Severity: Absent, very mild, mild, moderate and severe, where the normality of severity is absent.Frequency: At all times, almost at all times, 50% of the time, almost in no time, at any time. where the normality of the frequency is in no time.
Foreign Body Sensation (FBS)	will be evaluated at the end of the treatment at the final visit (day 10)	Foreign body sensation is a nominal variable that will be evaluated by direct questioning to the research subject, then it will be staged according to the following scale: Severity: Absent, very mild, mild, moderate and severe, where the normality of severity is absent. Frequency: At all times, almost at all times, 50% of the time, almost in no time, at any time. where the normality of the frequency is in no time.
Ocular Pruritus (P)	will be evaluated at the end of the treatment at the final visit (day 10)	Ocular pruritus is a nominal variable that will be evaluated by direct questioning to the research subject, then it will be staged according to the following scale: Severity: Absent, very mild, mild, moderate and severe, where the normality of severity is absent. Frequency: At all times, almost at all times, 50% of the time, almost in no time, at any time. where the normality of the frequency is in no time.
Chemosis	will be evaluated at the end of the treatment at the final visit (day 10)	The chemosis will be evaluated, as a nominal variable, by direct observation and it will be staged as present and absent, where the normality is that said variable is absent.

Countries

Mexico

Participant flow

Participants by arm

Arm	Count
PRO-087 Dosage: 1 drop in both eyes, 4 times a day during the waking period per 10 days Active principles: chondroitin sulfate 0.18%, sodium hyaluronate 0.1% ophthalmic solution made by Laboratorios Sophia, S.A. de C.V., transparent solution, free of visible particles in a sterile multi-dose bottle. PRO-087: The intervention period consists of a therapy with PRO-087administered 4 times a day in the waking period for 10 days. with a security call to day 13.	10
Xyel Ofteno Dosage: 1 drop in both eyes, 4 times a day during the waking period per 10 days, Active principles: Xanthan gum 0.9 mg, sodium chondroitin sulfate 1.0 ophthalmic solution made by Laboratorios Sophia, S.A. de C.V., transparent solution, free of visible particles in a sterile multi-dose bottle. Xyel Ofteno: The intervention period with active comparator drug consists of a therapy with Xyel administered 4 times a day in the waking period for 10 days. with a security call to day 13.	10
Systane Ultra Dosage: 1 drop in both eyes, 4 times a day during the waking period per 10 days Active principles: Polyethylene glycol 400 0.4%, propyleneglycol 0.3%, Ophthalmic solution, multi-dose dropper bottle, made by Alcon Laboratories, Inc. Systane Ultra: The intervention period with active comparator drug consists of a therapy with systane administered 4 times a day in the waking period for 10 days. with a security call to day 13.	9
Total	29

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002
Overall Study	cytology not readable	0	0	1

Baseline characteristics

Characteristic	PRO-087	Xyel Ofteno	Systane Ultra	Total
Age, Continuous	28.5 years STANDARD_DEVIATION 6.8	27.2 years STANDARD_DEVIATION 6.1	28.1 years STANDARD_DEVIATION 5.1	27.9 years STANDARD_DEVIATION 6
Ethnicity (NIH/OMB) Hispanic or Latino	10 Participants	10 Participants	9 Participants	29 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	0 Participants	0 Participants	0 Participants	0 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants	0 Participants
goblet cells	231.4 cells /mm2 STANDARD_DEVIATION 103.9	244.2 cells /mm2 STANDARD_DEVIATION 118.5	254.1 cells /mm2 STANDARD_DEVIATION 112.9	243.2 cells /mm2 STANDARD_DEVIATION 111.8
Intra Ocular Pressure (IOP)	13.6 mmHg STANDARD_DEVIATION 2.3	13.5 mmHg STANDARD_DEVIATION 2.4	13.9 mmHg STANDARD_DEVIATION 1.6	13.7 mmHg STANDARD_DEVIATION 6.3
Region of Enrollment Mexico	10 Participants	10 Participants	9 Participants	29 Participants
Sex: Female, Male Female	5 Participants	4 Participants	4 Participants	13 Participants
Sex: Female, Male Male	5 Participants	6 Participants	5 Participants	16 Participants
tear film breakup (BUT)	8.2 seconds STANDARD_DEVIATION 2.4	8.1 seconds STANDARD_DEVIATION 2.1	9.3 seconds STANDARD_DEVIATION 2.2	8.5 seconds STANDARD_DEVIATION 2.2

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk
deaths Total, all-cause mortality	0 / 10	0 / 10	0 / 10
other Total, other adverse events	5 / 10	4 / 10	5 / 10
serious Total, serious adverse events	0 / 10	0 / 10	0 / 10

Outcome results

Primary

Goblet Cell Density (GCD)

the cells will be measured per square millimeter, it is a continuous variable taken by means of cytology per impression, the normal value is higher than 500 cells per square millimeter